Oncomed pharmaceuticals inc (OMED)
Income statement / Quarterly
Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Sep'12Jun'12
Revenue:
Revenue

-

19,518

-

-

-

5,106

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration revenue

-

-

-

7,849

-

-

-

5,302

-

5,279

5,348

5,348

6,155

4,687

4,687

9,687

8,514

19,015

6,015

6,015

20,462

12,439

2,439

2,439

2,250

2,000

Other revenue

-

-

-

-

-

-

-

911

-

640

1,317

1,002

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration revenue - related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

493

493

493

5,493

5,493

Total revenue

-

-

6,870

7,849

-

-

6,195

6,213

-

5,919

6,665

6,350

6,838

4,687

4,687

9,687

-

-

-

-

18,983

12,932

2,932

2,932

7,743

7,493

Operating expenses:
Research and development

7,977

10,025

8,054

8,387

8,571

12,191

15,090

23,987

24,246

27,361

29,708

28,398

26,683

24,712

22,045

19,433

20,554

21,000

18,167

16,709

16,871

13,126

10,475

9,576

9,496

9,569

General and administrative

5,372

3,702

3,704

5,394

3,809

3,871

4,097

4,984

4,362

4,493

4,773

5,199

4,976

4,536

4,277

4,794

3,585

3,515

3,440

3,213

4,518

3,175

1,952

1,985

1,915

1,716

Restructuring charges

-

-

-

-

-

69

2,443

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

15,200

13,727

11,758

13,781

12,395

16,131

21,630

28,971

28,608

31,854

34,481

33,597

31,659

29,248

26,322

24,227

24,139

24,515

21,607

19,922

21,389

16,301

12,427

11,561

11,411

11,285

Loss from operations

-5,016

5,791

-4,888

-5,932

8,245

-11,025

-15,435

-22,758

-22,389

-25,935

-27,816

-27,247

-24,821

-24,561

-21,635

-14,540

-15,625

-5,500

-15,592

-13,907

-2,406

-3,369

-9,495

-8,629

-3,668

-3,792

Interest and other income, net

-

324

-

-

-

337

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

34

Interest and other income, net

-

-

524

363

-

-

214

154

-

80

129

37

27

94

27

22

12

49

6

38

7

-117

-149

31

-

-

Loss before income taxes

-4,665

6,115

-4,364

-5,569

8,368

-10,688

-15,221

-22,604

-22,336

-25,855

-27,687

-27,210

-24,794

-24,467

-21,608

-14,518

-

-5,451

-

-

-

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

Loss before provision for income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-15,586

-13,869

-

-3,486

-

-

-

-

Income tax provision (benefit)

1

0

-388

5

-1,095

4

4

4

-2

9

4

3

-15

12

12

11

-557

35

11

2

-

0

-

-

-

-

Interest and other income (expense), net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

13

-

Net loss

-4,666

6,115

-3,976

-5,574

9,463

-10,692

-15,225

-22,608

-22,334

-25,864

-27,691

-27,213

-24,779

-24,479

-21,620

-14,529

-15,056

-5,486

-15,597

-13,871

-4,343

-3,486

-9,644

-8,598

-3,655

-3,759

Net loss per common share, basic and diluted

-0.12

0.16

-0.10

-0.15

0.25

-0.28

-0.40

-0.61

-0.56

-0.77

-0.91

-0.90

-0.82

-0.81

-0.72

-0.49

-0.51

-0.18

-0.53

-0.47

14.97

-0.15

-8.83

-7.92

-3.45

-3.64

Shares used to compute net income (loss) per common share, basic

-

38,508

-

-

-

37,662

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Shares used to compute net income (loss) per common share, diluted

-

38,512

-

-

-

37,662

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Shares used to compute net loss per common share, basic and diluted

-

-

38,389

38,243

-

-

37,623

37,271

37,157

33,758

30,300

30,221

30,111

30,072

30,022

29,908

29,839

29,773

29,601

29,443

28,765

23,178

1,091

1,084

1,060

1,032